A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

NCT03267316 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

167

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer
Pancreatic Ductal Adenocarcinoma
Triple Negative Breast Cancer
Colorectal Cancer

Interventions

BIOLOGICAL: CAN04
DRUG: Cisplatin
DRUG: Gemcitabine
DRUG: Nab-paclitaxel
DRUG: Carboplatin
DRUG: Pemetrexed

Sponsor

Cantargia AB